Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
On our fourth episode of Oncology Onward, Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, sit down for a conversation with Robin Shah, MBA, cofounder and CEO of Thyme Care, which he started in 2020 with Bobby Green, MD, president and chief medical officer.
A biomedical engineer by education, Shah spent the first 5 years of his professional career as practice administrator and business manager at Gettysburg Cancer Center, working with his father, a community oncologist. From there, he moved to Flatiron Health and in July of 2017, helped to found OneOncology. Thyme Care was founded in July of 2020, and in August of this year announced a successful $60 million Series B round of investment capital.
Also an angel investor, this entrepreneur in oncology care innovation has been guided by a patient-first mentality and the principal goal of positively changing how patients experience the cancer care system.
For interview audio:
Listen above or on one of these podcast services:
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Robert F. Kennedy Jr Faces Senate Inquiry Over Deep Cuts to HHS Impacting FDA, CDC, NIH, CMS
April 2nd 2025A bipartisan letter from lawmakers questions the legality of Robert F. Kennedy Jr's HHS changes and the lack of clear communication regarding their potential impact on American health.
Read More